Essen BioScience (part of Sartorius), is a team of engineers and biologists with deep expertise in cell-based assays. They invent, manufacture, supply and support cell-based assay instrumentation, reagents and protocols.
Discover
Related topics
May 30, 2023
In this webinar, Sebastien Clerc, PM in Cellenion, presents technologies Cellen ONE and Sphero ONE
Webinar: Multimodal tissue imaging and machine learning to advance precision medicine
May 17, 2023
Join us for this webinar to learn how the Orion spatial biology imaging platform was used to identify prognostic...
Cellenion’s solutions for isolation and sample preparation from Cells all the way to Spheroids
May 9, 2023
In this webinar, you will get an overview of Cellenion’s solutions for single cell and single 3D models applications:...
Recorded webinar: Anesthesia Considerations in Small Animal Imaging
Mar 13, 2023
Anesthesia settings and operation of Optical Imaging Systems: methods, animal handling, safety and regulatory...
NanoCellect Webinar: Optimizing the Cell Line Development Process with Microfluidic Cell Sorting
Mar 3, 2023
Single-cell selection and cloning are required for bioengineering workflows such as antibody production, cell therapy,...
Webinar: Spatial Biology and immunofluorescence to study human pancreata in in type 1 diabete
Feb 9, 2023
In this webinar, Dr. Quesada-Masachs from La Jolla Institute for Immunology reveals the image analysis pipeline that...
Advances in Leukemia research using shear flow and Bioflux system
Feb 3, 2023
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Webinar: Dose Reduction and Image Enhancement in Preclinical Mouse Imaging using Deep Learning
Jan 31, 2023
In this webinar, ir. Florence Muller (Ghent University - University of Pennsylvania) is presenting two recent studies...
Practical aspects of an imaging study: live in vivo scanning
Nov 11, 2022
In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Aug 21, 2017
September 7, 2017, 7 pm CEST
Chia-Wei Li, PhD, The University of Texas M. D. Anderson Cancer Center
Here we reveal PD-L1’s immunosuppression activity is stringently modulated by the spatial restraints between ubiquitination and N-linked glycosylation. We identified GSK3beta as a novel PD-L1 interacting protein capable of inducing phosphorylation dependent proteasome degradation. The essence of PD-L1 N192, N200 and N219 glycosylation suggests it antagonizes GSK3beta binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3beta and beta-TrCP. More importantly, activation of GSK3beta-mediated PD-L1 degradation by TKI can reduce membrane PD-L1 expression and thereby enhance anti-tumor immunity. To test T cell-mediated cancer cell killing in vitro, we employed a time lapse microscopy, IncuCyte, to monitor RFP-tagged BT549 cells and activated PBMC interaction over a five day period. Massive cancer cell death was observed in glycosylation deficient cancer cells, suggesting glycosylation of PD-L1 is required for its immunosuppression. Together, our results link ubiquitination and glycosylation pathways with stringent regulation of PD-L1, proposing a new therapeutic strategy to enhance cancer immune therapy efficacy.
Learning objectives:
Related technologies: BioImaging
Brand profile
Essen BioScience (part of Sartorius), is a team of engineers and biologists with deep expertise in cell-based assays. They invent, manufacture, supply and support cell-based assay instrumentation, reagents and protocols.
More info at:
www.essenbioscience.com/